Tenecteplase
Tenecteplase, sold as TNKase, is a clot-dissolving medicine, a tissue plasminogen activator, given into a vein. The US label read lists two uses, both in adults: the treatment of acute ischemic stroke, and reducing the risk of death associated with acute ST-elevation myocardial infarction (STEMI). The label says it binds to fibrin and converts plasminogen to plasmin.
Also called TNKase · TNK-tPA
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 259280; MeSH descriptor D000077785 is Tenecteplase. It is a biologic: the openFDA record carries no UNII, and RxClass returned no FDA class for it, so the class rests on the label's own words (it calls tenecteplase a tissue plasminogen activator and refers to related thrombolytic agents), and MeSH lists Fibrinolytic Agents (D005343) among its pharmacological actions. The label read is the Genentech, Inc. label for TNKase, application BLA103909, effective 2025-12-15 in openFDA. This page records label indications and the class only: no trial result and no dose is given. This is a regulatory record, not a finding about how well the medicine works.
Trials at a glance
The figures count the 51 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 51
- Phase 3 or 4
- 39
- Recruiting
- 18
- Regulatory decisions
- 0
| Phase | Recruiting | Not yet recruiting | Completed | Terminated | Unknown status | All statuses |
|---|---|---|---|---|---|---|
| Phase 2 | 2 | 0 | 6 | 0 | 1 | 9 |
| Phase 2/3 | 2 | 0 | 1 | 0 | 0 | 3 |
| Phase 3 | 13 | 6 | 11 | 3 | 3 | 36 |
| Phase 4 | 1 | 0 | 1 | 0 | 1 | 3 |
| All phases | 18 | 6 | 19 | 3 | 5 | 51 |
Conditions these trials study
Sponsors with the most trials
About this drug
- Level
- Substance
- Mechanism
- The label says tenecteplase is a modified form of human tissue plasminogen activator that binds to fibrin and converts plasminogen to plasmin.
Claims and evidence
Context Adults for whom the US label of tenecteplase (TNKase) lists an indication: acute ischemic stroke, acute ST-elevation myocardial infarction
- Recipient
- Adult
- Population
- Adult patients described in the indications sections of the label.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults, as the passages read state
- Follow-up
- Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Adults with acute ischemic stroke (AIS)
- Adults with acute ST elevation myocardial infarction (STEMI)
- Excluded
- None stated
The US label of TNKase (tenecteplase), in the Genentech, Inc. version dated 2025-12-15 in openFDA, describes the medicine as a tissue plasminogen activator (tPA) and lists it, in adults, for the treatment of acute ischemic stroke (AIS) and to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI).
Applies to Adult Adults for whom the US label of tenecteplase (TNKase) lists an indication: acute ischemic stroke, acute ST-elevation myocardial infarction
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label has no boxed warning section in openFDA; time limits, contraindications, doses, interactions and bleeding warnings were not read. openFDA also lists a second TNKase record with only the myocardial infarction indication. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (LB-04).
- Retrieved
- Source effective date
- 2025-12-15
- Source state
- Current
- Version fingerprint
5e913aaff2ba6e28550a73f2122bc8054e66c3b05b3d92a2f9ca50b37a27ca09- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.1 Acute Ischemic Stroke
- How it applies
- Label passage quoted in the research quote table (LB-05).
- Retrieved
- Source effective date
- 2025-12-15
- Source state
- Current
- Version fingerprint
5e913aaff2ba6e28550a73f2122bc8054e66c3b05b3d92a2f9ca50b37a27ca09- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.2 Acute ST Elevation Myocardial Infarction
- How it applies
- Label passage quoted in the research quote table (LB-06).
- Retrieved
- Source effective date
- 2025-12-15
- Source state
- Current
- Version fingerprint
5e913aaff2ba6e28550a73f2122bc8054e66c3b05b3d92a2f9ca50b37a27ca09- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20251215.
- Retrieved
- Source effective date
- 2025-12-15
- Source state
- Current
- Version fingerprint
5e913aaff2ba6e28550a73f2122bc8054e66c3b05b3d92a2f9ca50b37a27ca09- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
TNKASE
No label from the application holder was found in the openFDA label dataset for application BLA103909. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists treatment of acute ischemic stroke in adults as an indication: Ischemic stroke
Applies to Adult Adults for whom the US label of tenecteplase (TNKase) lists an indication: acute ischemic stroke, acute ST-elevation myocardial infarction
The US label of TNKase (tenecteplase), in the Genentech, Inc. version dated 2025-12-15 in openFDA, describes the medicine as a tissue plasminogen activator (tPA) and lists it, in adults, for the treatment of acute ischemic stroke (AIS) and to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI).Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label has no boxed warning section in openFDA; time limits, contraindications, doses, interactions and bleeding warnings were not read. openFDA also lists a second TNKase record with only the myocardial infarction indication. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists reducing the risk of death associated with acute ST elevation myocardial infarction in adults as an indication: ST-elevation heart attack (STEMI)
Applies to Adult Adults for whom the US label of tenecteplase (TNKase) lists an indication: acute ischemic stroke, acute ST-elevation myocardial infarction
The US label of TNKase (tenecteplase), in the Genentech, Inc. version dated 2025-12-15 in openFDA, describes the medicine as a tissue plasminogen activator (tPA) and lists it, in adults, for the treatment of acute ischemic stroke (AIS) and to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI).Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label has no boxed warning section in openFDA; time limits, contraindications, doses, interactions and bleeding warnings were not read. openFDA also lists a second TNKase record with only the myocardial infarction indication. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 1
-
A biologics license application (BLA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
Registry trials 51
Record details
- Record id
cardio:tenecteplase- Content hash
f3cea7d45e4c539a8b89bfed9214be34c8d55a1d72b93a649ed526bc94fc6f6a